持续血糖监测 (CGM) 市场：2025 年至 2030 年预测

持续血糖监测 (CGM) 市场预计将从 2025 年的 89.84 亿美元成长到 2030 年的 171.19 亿美元，复合年增长率为 13.76%。

全球持续血糖监测 (CGM) 市场正经历强劲成长，这得益于全球糖尿病盛行率的上升。 CGM 系统利用皮下感测器和无线发送器即时追踪血糖值，为糖尿病管理和调整患者治疗方法提供关键数据。糖尿病盛行率的上升、技术进步以及政府的支持倡议推动了该市场的发展，使 CGM 成为 2030 年糖尿病治疗的关键工具。

市场驱动因素

糖尿病盛行率不断上升

久坐的生活方式、胰岛素抗性和遗传因素是糖尿病发生率上升的主要驱动因素。连续血糖监测 (CGM) 设备使患者和医疗保健提供者能够密切监测血糖值，从而促进及时干预。政府计画和补贴正在改善 CGM 设备的可及性，特别是针对 1 型糖尿病患者，并鼓励其推广应用。全球糖尿病患者人数不断增长，预计到 2030 年将达到 6.43 亿，这凸显了对 CGM 解决方案日益增长的需求，尤其是在患病率快速上升的中低收入国家。

近期动态

企业投入大量资金，加速了动态血糖监测（CGM）的商业化和技术创新。配备更小巧、更可靠感测器的先进CGM设备等产品的推出，正在提升用户的便利性和准确性。联网自动化监测系统等创新技术即将问世，这些系统有望与智慧型设备无缝整合。长寿命感测器比传统的短期系统更易于使用，因此越来越受欢迎，并透过提高患者依从性和降低更换成本，进一步推动市场成长。

市场区隔

由于糖尿病盛行率不断上升，以及优惠的报销政策带来的监测设备需求，糖尿病领域在动态血糖监测 (CGM) 市场占据主导地位。 CGM 的持续数据提供功能可帮助第 1 型和第 2 型糖尿病患者减少失明、肾衰竭和心血管问题等併发症。无针生物感测器和应用程式整合设备等最尖端科技的引入，正在提升该市场的吸引力，尤其是在糖尿病负担较重的地区。

区域展望

北美凭藉其日益增长的老年人口、高糖尿病盛行率以及对先进血糖监测解决方案的大量投资，引领CGM市场。美国是CGM市场的主要贡献者，许多公司正大力投资开发创新的CGM平台。受中国、印度等国糖尿病盛行率上升以及医疗基础设施改善的推动，亚太地区有望迎来快速成长。欧洲、中东和非洲以及南美也正在透过其区域性努力来满足糖尿病治疗需求，为满足糖尿病治疗需求做出贡献。

市场展望

预计到2030年，CGM市场将大幅扩张，这得益于糖尿病盛行率的上升、技术创新和政府支持的推动。北美市场的主导地位以及亚太地区的快速成长凸显了关键机会。补贴和成本效益技术的进步正在缓解诸如设备成本高等挑战。市场发展轨迹凸显了CGM在全球糖尿病管理转型中发挥的重要作用，持续的研发将维持这一发展动能。

本报告的主要优点

• 深刻分析：获得涵盖主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、垂直行业和其他细分市场。
• 竞争格局：了解主要企业采用的策略策略，并了解正确策略的市场渗透潜力。
• 市场趋势和驱动因素：探索动态因素和关键市场趋势以及它们将如何影响未来的市场发展。
• 可行的建议：利用洞察力进行策略决策并在动态环境中开闢新的业务流和收益。
• 受众范围广：对于新兴企业、研究机构、顾问、中小企业和大型企业来说都是有益且具成本效益的。

它有什么用途？

产业和市场考量、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范与影响、新产品开发、竞争影响

调查范围

• 2020 年至 2024 年的历史数据和 2025 年至 2030 年的预测数据
• 成长机会、挑战、供应链前景、法律规范与趋势分析
• 竞争定位、策略和市场占有率分析
• 收益成长和预测细分市场和区域分析（包括国家）
• 公司概况（策略、产品、财务、主要发展等）

目录

第一章执行摘要

第二章市场概述

• 市场概览
• 市场定义
• 调查范围
• 市场区隔

第三章 经营状况

• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析
• 产业价值链分析
• 政策法规
• 策略建议

第四章 技术展望

第五章。按应用分類的持续血糖监测市场

• 介绍
• 糖尿病患者
• 重症患者

6. 持续血糖监测市场（依最终用户产业）

• 介绍
• 医院
• 诊断中心和诊所
• 居家护理
• 其他的

7. 持续血糖监测市场（按地区）

• 介绍
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他的
• 欧洲
  • 德国
  • 法国
  • 英国
  • 西班牙
  • 其他的
• 中东和非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他的
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 印尼
  • 泰国
  • 其他的

第八章竞争格局及分析

• 主要企业和策略分析
• 市场占有率分析
• 合併、收购、协议和合作
• 竞争对手仪表板

第九章：公司简介

• Dexcom, Inc.
• Abbott Laboratories
• Medtronic plc
• Senseonics Holdings, Inc.
• Ascensia Diabetes Care
• Insulet Corporation
• Roche Diabetes Care, Inc.
• Tandem Diabetes Care, Inc.
• GlySens Incorporated
• Echo Therapeutics, Inc

第十章 附录

• 货币
• 先决条件
• 基准年和预测年时间表
• 相关人员的主要利益
• 调查方法
• 简称

The Continuous Glucose Monitoring (CGM) Market is expected to grow from USD 8.984 billion in 2025 to USD 17.119 billion in 2030, at a CAGR of 13.76%.

The global continuous glucose monitoring (CGM) market is experiencing robust growth, driven by the escalating prevalence of diabetes worldwide. CGM systems, utilizing subcutaneous sensors and wireless transmitters to track blood glucose levels in real time, provide critical data for managing diabetes and tailoring patient treatments. The market is propelled by increasing diabetes rates, technological advancements, and supportive government initiatives, positioning CGM as a vital tool in diabetes care through 2030.

Market Growth Drivers

Growing Prevalence of Diabetes

The rising incidence of diabetes, fueled by sedentary lifestyles, insulin resistance, and genetic factors, is a primary driver. CGM devices enable patients and healthcare providers to monitor glucose levels closely, facilitating timely interventions. Government programs and subsidies enhance access to CGM devices, particularly for type 1 diabetes patients, boosting adoption. The projected increase in global diabetes cases-expected to reach 643 million by 2030-underscores the growing demand for CGM solutions, especially in low- and middle-income countries where prevalence is rising rapidly.

Recent Developments

Significant investments by companies are accelerating CGM commercialization and innovation. Product launches, such as advanced CGM devices with smaller, more reliable sensors, are enhancing user convenience and accuracy. Innovations like networked and automated monitoring systems are on the horizon, promising seamless integration with smart devices. Long-lasting sensors, extending usability beyond traditional short-term systems, are gaining traction, further driving market growth through improved patient compliance and reduced replacement costs.

Market Segment Analysis

The diabetes patient segment dominates the CGM market, driven by the increasing prevalence of diabetes and demand for monitoring devices with favorable reimbursement policies. Type 1 and type 2 diabetes patients benefit from CGM's ability to provide continuous data, reducing complications like blindness, kidney failure, and cardiovascular issues. The introduction of cutting-edge technologies, such as needle-free biosensors and app-integrated devices, enhances market appeal, particularly in regions with high diabetes burdens.

Regional Insights

North America leads the CGM market, fueled by a growing geriatric population, high diabetes prevalence, and substantial investments in advanced glucose monitoring solutions. The U.S. is a key contributor, with companies allocating significant funds to develop innovative CGM platforms. The Asia Pacific region is poised for rapid growth, driven by rising diabetes rates and improving healthcare infrastructure in countries like China and India. Europe, the Middle East, Africa, and South America also contribute, with regional efforts to address diabetes care needs.

Market Outlook

The CGM market is set for significant expansion through 2030, driven by diabetes prevalence, technological innovations, and government support. North America's dominance and Asia Pacific's rapid growth highlight key opportunities. Challenges, such as high device costs, are being mitigated through subsidies and advancements in cost-effective technologies. The market's trajectory underscores CGM's critical role in transforming diabetes management globally, with ongoing R&D ensuring sustained momentum.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2020 to 2024 & forecast data from 2025 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

USA CGM Market Segmentation:

By Application

• Diabetes Patients
• Critical Patients

By End-User Industry

• Hospitals
• Diagnostic Centers & Clinics
• Home Care
• Others

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. CONTINUOUS GLUCOSE MONITORING MARKET BY APPLICATION

• 5.1. Introduction
• 5.2. Diabetes Patients
• 5.3. Critical Patients

6. CONTINUOUS GLUCOSE MONITORING MARKET BY END-USER INDUSTRY

• 6.1. Introduction
• 6.2. Hospitals
• 6.3. Diagnostic Centers & Clinics
• 6.4. Home Care
• 6.5. Others

7. CONTINUOUS GLUCOSE MONITORING MARKET BY GEOGRAPHY

• 7.1. Introduction
• 7.2. North America
  • 7.2.1. USA
  • 7.2.2. Canada
  • 7.2.3. Mexico
• 7.3. South America
  • 7.3.1. Brazil
  • 7.3.2. Argentina
  • 7.3.3. Others
• 7.4. Europe
  • 7.4.1. Germany
  • 7.4.2. France
  • 7.4.3. United Kingdom
  • 7.4.4. Spain
  • 7.4.5. Others
• 7.5. Middle East and Africa
  • 7.5.1. Saudi Arabia
  • 7.5.2. UAE
  • 7.5.3. Others
• 7.6. Asia Pacific
  • 7.6.1. China
  • 7.6.2. India
  • 7.6.3. Japan
  • 7.6.4. South Korea
  • 7.6.5. Indonesia
  • 7.6.6. Thailand
  • 7.6.7. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 8.1. Major Players and Strategy Analysis
• 8.2. Market Share Analysis
• 8.3. Mergers, Acquisitions, Agreements, and Collaborations
• 8.4. Competitive Dashboard

9. COMPANY PROFILES

• 9.1. Dexcom, Inc.
• 9.2. Abbott Laboratories
• 9.3. Medtronic plc
• 9.4. Senseonics Holdings, Inc.
• 9.5. Ascensia Diabetes Care
• 9.6. Insulet Corporation
• 9.7. Roche Diabetes Care, Inc.
• 9.8. Tandem Diabetes Care, Inc.
• 9.9. GlySens Incorporated
• 9.10. Echo Therapeutics, Inc

10. APPENDIX

• 10.1. Currency
• 10.2. Assumptions
• 10.3. Base and Forecast Years Timeline
• 10.4. Key Benefits for the Stakeholders
• 10.5. Research Methodology
• 10.6. Abbreviations